<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480126</url>
  </required_header>
  <id_info>
    <org_study_id>2018/02/7</org_study_id>
    <nct_id>NCT03480126</nct_id>
  </id_info>
  <brief_title>Herbal Teas on Bone Health in an Osteopenic Population</brief_title>
  <acronym>OsTea</acronym>
  <official_title>Assessing the Efficacy of Herbal Teas on Bone Health in an Osteopenic Population: OsTea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paula Witt-Enderby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duquesne University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duquesne University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project goal is to identify if herbal teas consumed 3 times per day over a period of
      three months can improve these markers of bone health as well as improve QOL compared to
      women taking placebo by increasing osteoblast activity, decreasing osteoclast activity,
      increasing nocturnal melatonin levels and by decreasing CRP and cortisol levels. Our central
      hypothesis is that these herbal teas will improve both objective and subjective measures of
      bone health in an osteopenic population not taking this regimen by reducing osteoclast
      activity and increasing osteoblast activity and by reducing stress and anxiety.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effect of 3 month Herbal Tea on Changes in Human Type 1 Collagen C-telopeptide (CTx) levels</measure>
    <time_frame>3 months</time_frame>
    <description>Urinary CTx levels will be measured at times month 0 (baseline) and month 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effect of 3 month Herbal Tea on Changes in Human Procollagen Type 1 Intact N-terminal Propeptide (Total P1NP) levels</measure>
    <time_frame>3 months</time_frame>
    <description>Urinary P1NP levels will be measured at times month 0 (baseline) and month 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effect of 3 month Herbal Tea on Changes in the Ratio of CTx:P1NP</measure>
    <time_frame>3 months</time_frame>
    <description>Urinary CTx:P1NP levels will be measured at times month 0 (baseline) and month 3</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Herbal Tea 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Tea should will be ingested 3 times per day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herbal Tea 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Herbal Tea A will be ingested 3 times per day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herbal Tea 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Herbal Tea B will be ingested 3 times per day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herbal Tea 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Herbal Tea C will be ingested 3 times per day for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Herbal Teas</intervention_name>
    <description>Organic caffeine-free herbal tea</description>
    <arm_group_label>Herbal Tea 1</arm_group_label>
    <arm_group_label>Herbal Tea 2</arm_group_label>
    <arm_group_label>Herbal Tea 3</arm_group_label>
    <arm_group_label>Herbal Tea 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female with osteopenia (T-score between -1.0 and -2.5)

          -  at least 18 years of age

          -  must be willing to drink tea three times a day for 3 months

          -  must also be willing to come to the study location to provide urine samples on 4
             occasions (baseline, month 1, month 2, and month 3),

          -  must also be willing to come to the study location to provide salivary samples on 4
             occasions (baseline, month 1, month 2, and month 3),

          -  must also be willing to come to the study location to have their blood pressure taken
             on 4 occasions (baseline, month 1, month 2, and month 3)

          -  must be willing to come to the study location to provide complete questionnaires on 4
             occasions (baseline, month 1, month 2, and month 3)

          -  must be willing to maintain daily diary for 4 months.

        Exclusion Criteria:

          -  Women or men with osteoporosis

          -  Women or men with osteopenia due to hyperparathyroidism, multiple myeloma, metastatic
             bone disease, chronic steroid use

          -  Women or men who are on any bone therapies (i.e. bisphosphonates, SERMs, hormone
             therapy, teriparatide, and denusumab)

          -  Women or men with COPD

          -  Women or men who smoke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula A Witt-Enderby, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duquesne University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula A Witt-Enderby, PhD</last_name>
    <phone>412-396-346</phone>
    <email>wittp@duq.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fahima Munmun, MS</last_name>
    <phone>412-396-4296</phone>
    <email>munmunf@duq.edu</email>
  </overall_contact_backup>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duquesne University</investigator_affiliation>
    <investigator_full_name>Paula Witt-Enderby</investigator_full_name>
    <investigator_title>Professor of Pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

